Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Beam Therapeutics Inc BEAM

Healthcare Biotechnology
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BEAM)

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire March 26, 2024

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

GlobeNewswire February 28, 2024

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

GlobeNewswire February 27, 2024

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire February 5, 2024

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

GlobeNewswire January 8, 2024

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

GlobeNewswire December 14, 2023

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

GlobeNewswire November 8, 2023

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

GlobeNewswire November 8, 2023
View More News ››

Opinion & Analysis (NDAQ:BEAM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BEAM)

Buy Recommendation Issued On BEAM By Citigroup

BREAKING NEWS: $BEAM Buy Recommendation Issued On BEAM By Citigroup2024-04-02 20:15:01 ET Citigroup analyst issues BUY recommendation...
whytestocks - April 2, 2024
View more Bullboard ››

Goldflare Exploration Inc

Goldflare Exploration Inc

Goldflare Exploration Inc. is a Canada-based mineral exploration company. The Company specializes in gold exploration in the ...
View More »